Irribow is a serotonin 5-HT3 receptor antagonist discovered by Astellas. According to the company, Irribow improves abnormal defaecation associated with the acceleration of intestinal transit by inhibiting 5-HT3 receptor selectively. It is also said to improve visceral hypersensitivity by suppressing the transmission of intestinal nociception.
Astellas expects to provide a new option for irritable bowel syndrome (IBS) medication. The launch timing will be announced after it appears in the NHI drug price list.